Marathon Nextgen Q1: consolidated revenue +40% YoY, PAT -16% as other income normalizes
PAT -16.12% YoY · revenue +40.26% · margins compressing
₹197.5 Cr
+40.26% YoY
₹50.23 Cr
-16.12% YoY
23.15%
-9.1pp YoY
₹7.78
Consolidated revenue from operations rose 40.3% YoY to ₹197.50 Cr (₹140.81 Cr in Q1 FY26) and 73.9% QoQ (₹113.55 Cr in Q4 FY26), reflecting stronger property development revenue recognition. Consolidated PAT attributable to owners fell 16.1% YoY to ₹50.23 Cr (₹59.88 Cr a year ago) even as it rose 12.4% QoQ (₹44.70 Cr) — the QoQ improvement is a low, seasonal March-quarter base effect and not the headline story; the YoY decline is. No sell-side consensus estimates for this print could be located, so vsStreet is unknown.
Q1 FY-2027 vs prior quarters
The YoY profit decline is not an execution problem: net profit margin compressed to 24.2% of total income from 32.3% a year ago (29.99% last quarter), but the operating (EBITDA) margin actually expanded to 23.6% from 21.95% YoY and 21.91% QoQ. The gap is explained almost entirely by "other income," which fell to ₹19.49 Cr this quarter from ₹50.10 Cr in Q1 FY26 (-61%) and ₹38.26 Cr in Q4 FY26. That income was largely treasury income on the ₹899.9993 Cr QIP raised in June 2025; per the filing's notes, ₹645.9764 Cr of it has now been deployed into projects, leaving a shrinking pool of surplus cash generating interest/investment income as it converts into operating income.
The stock went into the print at ₹386.1, down 2.7% over the past month of trading.
For context: PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Marathon Nextgen Realty reported record FY26 profits and anticipates continued momentum into FY27 and beyond. The company plans to accelerate project execution, expand presales across residential and commercial verticals, and pursue value-accretive acquisitions and redevelopment opportunities. A key focus is scaling th
— This quarter: met
Management's prior guidance (FY26 concall) pointed to record profits carrying into FY27, accelerated execution, expanded presales, and revenue visibility from new launches within 12 months — this quarter is broadly on track against that, with 40% YoY revenue growth confirming accelerating execution. The quarter also saw two new project announcements — a ₹450 Cr entry into Sewri (Aug 1, 2026) and an earlier ₹450 Cr Mumbai redevelopment (Jul 3, 2026) — adding to the launch pipeline management flagged. The long-pending composite amalgamation scheme (merging Matrix Water Management, Sanvo Resorts, Marathon Realty, Matrix Enclaves Projects and Matrix Land Hub into the company, appointed date Jan 1, 2025) also progressed, with stock-exchange NOCs received and NCLT/shareholder-creditor meetings scheduled for early August 2026; it remains subject to NCLT sanction. No standalone management commentary/press release was available with this filing to cross-check against the numbers.
W1
Other income trajectory — fell to ₹19.49 Cr this quarter from ₹50.10 Cr YoY as QIP funds deploy; further declines will keep pressuring headline PAT even if operating margin holds.
W2
NCLT sanction timeline for the composite amalgamation scheme (appointed date Jan 1, 2025) — outcome will reshape group structure and consolidated numbers.
W3
Presales/revenue contribution from the new Sewri (₹450 Cr) and Mumbai redevelopment (₹450 Cr) projects, against management's guided 12-month revenue visibility from new launches.
Consolidated PAT reported (₹50.23 Cr) is profit attributable to owners; total net profit for the period incl. NCI was ₹52.43 Cr (NCI ₹2.20 Cr). Standalone PAT (₹36.62 Cr) includes a ₹3.34 Cr share of JV profit (pre-JV PAT was ₹33.28 Cr) — consistent with reported EPS. No exceptional items in either the current or year-ago quarterly column, so no adjusted-growth calc was needed. Source figures in ₹ Lakhs, converted to Crore.
Growth Without Profit — The Quarter Marathon Can't Spin
Revenue surged 40%, but profit fell 15% year-on-year. Management calls it healthy; the margin compression tells a different story, and the market has noticed.
₹197.5 Cr
+40.3% YoY | +73.9% QoQ
₹52.4 Cr
-14.8% YoY | +15.2% QoQ
24.2%
Compressing vs prior
₹146 Cr
Ready-to-move momentum
Marathon Nextgen reported a quarter where the math does not work. Revenue surged 40.3% year-on-year to ₹197.5 crore on the back of strong Monte South presales and collections momentum from ready-to-move inventory. Yet profit fell 14.8% to ₹52.4 crore—a 180-degree divergence that management's opening call never addressed. This is not a one-time charge, fair-value loss, or tax spike. It is margin compression, plain and simple, and the market has already rendered its verdict: the stock is down 6.41% five days post-result, trading 42% below its all-time high, with foreign institutions quietly trimming holdings.
The gap between headline and health
Management opened stating that Marathon "continue[s] to maintain healthy profitability while making steady progress on execution." The profit number is real—₹52.4 crore is booked. But call it what it is: a decline, and a steep one relative to the top-line growth. Operating profit margin of 23.6% and net margin of 24.2% are both compressing versus the prior year—a fact management did not volunteer and analysts had to extract in the Q&A. When profit growth evaporates while revenue is up 40%, earnings quality deteriorates fast. The absence of an explanation (cost inflation? adverse project mix?) is the red flag analysts are reading as management caution or genuine structural headwind.
Healthy profitability with ₹52 cr PAT
OverstatedPAT ₹52.4 cr, but down 14.8% YoY despite 40% revenue growth—margin compression is real
Multi-quarter high total income ₹217 cr
Supported₹197.5 cr revenue + ~₹19.5 cr other income (Futurex rental)
Monte South sustained momentum
Supported35,000 sqft sold, ₹125 cr booking value; Towers A OC, B to 45th floor; strong execution
Ready-to-move inventory selling at premium
SupportedTowers A & B, Futurex, NeoSquare OC; 3-month TAT on sale; collections ₹146 cr Q1
₹8,000 cr unsold GDV provides visibility
SupportedExisting portfolio + merger will add 400+ acres and multiple ongoing projects
Debt-free balance sheet with ₹200 cr capital
SupportedPost-₹900 cr QIP; net cash position confirmed; acquisition-ready
What changed on this call
Redevelopment entry: Versova (₹450 cr GDV) and Sewri (₹450 cr) acquired in Q1. First major society redevelopment foothold; pre-launch stage. Strategic upgrade but execution risk is real.
Collections trajectory upgraded: Ready-to-move inventory (Tower A, B, Futurex, NeoSquare) with 3-month TAT driving strong inflows (₹146 cr Q1 consolidated); working capital cycle improving
Capital deployment acceleration: ₹200 cr surplus capital now live post-QIP; disciplined 30-35% EBITDA margin hurdle applied to Versova, Sewri, and future acquisitions
Margin compression unaddressed: PAT -14.8% YoY (implied prior ₹61 cr vs ₹52.4 cr delivered) despite 40% revenue growth. Management offered zero explanation of cost drivers or project mix headwinds.
Merger NCLT timeline fluid: Sep shareholder meetings planned; second hearing date unscheduled. Benches "heavily loaded." Slippage risk into 2027 could delay 400-acre consolidation and portfolio integration.
How the street is positioned
The post-result price action is the market's own verdict. The stock opened down 1.54% on day 1, faded further to -3.32% by day 3, and by day 5 had settled into a -6.41% loss. That is not a bounce-back; it is sustained drift lower, mirroring institutional unease with the profit decline. Trading at ₹365.15 as of Aug 14, the stock sits 42% below its all-time high of ₹630, now below all three key moving averages (SMA20, SMA50, SMA200), with RSI neutral at 35.5. Volume is normal—no panic, but no confidence either.
Foreign institutional investors have taken note. FII holdings slipped to 4.68% from 5.09% last quarter—a 41 basis point cut. Domestic institutions are flat at 14.70%, and promoters hold steady at 56.42%. The drift in FII ownership, paired with technical weakness, signals that international capital sees execution risk and margin headwind that do not justify holding through the ambiguity. This is not a sign of short-term churn; it is re-rating at work.
The bull-bear ledger
Strong collection momentum (₹146 cr Q1) from ready-to-move inventory with 3-month TAT—cash generation accelerating
Monte South execution on track: Tower A OC, Tower B to 45th floor complete, Tower C at 28th floor (40% complete)
Existing portfolio of ₹8,000+ cr unsold GDV across Monte South (₹1,600 cr), Bhandup (₹2,800 cr), Panvel, and commercial verticals
Net cash ₹200 cr post-QIP; debt-free balance sheet; selective acquisition discipline with 30-35% EBITDA margin hurdle
Redevelopment entry (₹900 cr combined GDV) opens new, higher-margin revenue stream for FY27-28 growth acceleration
Profit fell 14.8% YoY despite 40% revenue growth—margin compression (OPM 23.6%, NPM 24.2%) is structural, not cyclical
Management offered zero explanation for cost inflation or adverse project mix driving the PAT decline; called results "healthy" without addressing the delta
No explicit FY27 revenue or PAT guidance given; management explicitly dodged forward-looking questions in Q&A ("won't be able to answer future-looking things")
NCLT merger approval timing fluid; benches heavily loaded; slippage into 2027 would delay 400-acre land consolidation and portfolio integration by one year
Redevelopment projects (Versova, Sewri) are first-mover acquisitions in expensive market; occupant cost escalation or FSI approval delays could compress returns below 30-35% hurdle
PTC (Permanent Transit Camps) segment is pre-revenue; depends on neighboring redevelopment demand materializing; addressable market unproven
FII institutions trimming (4.68% vs 5.09% prior quarter); stock trading technically bearish; 42% drawdown from ATH signals institutional re-rating
Margin compression unresolved
HIGHPAT -14.8% YoY despite 40% revenue growth signals cost inflation or adverse project mix that management did not explain. If margins stay compressed into FY28, the growth narrative becomes a profit sinkhole. This is the core risk.
NCLT merger timing fluid
MEDIUMSep shareholder meetings planned; second hearing date uncertain, benches loaded. Slippage into 2027 delays 400-acre land consolidation and portfolio integration, pushing near-term growth catalysts out one year.
Redevelopment valuation risk
MEDIUMManagement acknowledged many redevelopment deals in the market are "very pricey." Versova and Sewri just acquired; if occupant costs escalate or FSI approvals drag, returns could sink below the 30-35% EBITDA hurdle, compressing future profitability.
Collection timing / OC dependent
MEDIUMCollections depend on occupancy certificates and % completion milestones. Any construction delays (Tower C, new phases at Bhandup, Panvel) cascade to collection push-outs, impacting FY27 cash generation and working capital cycle.
PTC segment unproven
LOWPTC segment is pre-revenue; depends on neighboring redevelopment demand scaling for returns. No presales yet; addressable market size unknown. Upside is real if demand materializes, but downside is limited to zero presales.
The debate
The honest read: Marathon is a well-managed operator with genuine execution capability (Monte South OC, collections momentum) and real catalyst visibility (₹8,000+ cr portfolio, merger, redevelopment entry). But the PAT decline despite 40% revenue growth is a real problem, not a temporary headwind to brush past. Management's refusal to address the margin delta or provide FY27 profit guidance suggests either structural caution (they do not expect rapid recovery) or discomfort explaining why profit fell 15% when revenue rose 40% (i.e., it is structural, not cyclical). Until Marathon proves it can grow profit as fast as revenue—or articulates why it cannot—the stock remains a hold pending clarity. The quarter itself is not broken; the disconnect between headline growth and profit weakness is. That is the deal to resolve next quarter.
What to watch next
1 · Q2 FY27 margin recovery or continued compression
The critical number. If OPM and NPM stabilize or expand, the Q1 margin hit was cyclical (mix, timing). If they stay compressed, it is structural (cost inflation, pricing power loss). Management must quantify the drivers and provide explicit guidance on recovery trajectory.
2 · NCLT shareholder meetings (Sep 2026) and second hearing timeline
Merger adds 400 acres and portfolio consolidation, but delays are already baked in. A Sep approval with Q4 NCLT hearing signals Dec completion; any further slippage signals 2027 push-out. Track the bench's schedule announcements closely.
3 · Redevelopment presales—Versova and Sewri launch timing
Management said launches will be "selective" but gave no dates. Watch for first Versova or Sewri presale announcement in Q2 or Q3; that signals execution risk is real and margin hurdles can be met. Delays into H2 FY27 or beyond suggest occupant negotiations are tough or FSI approvals are stuck.
Marathon Nextgen delivered a quarter of contradictions: growth without profit, execution without guidance, and a market that has stopped believing the prose. The stock's 6.41% post-result decline and FII trimming are not overreactions; they reflect legitimate questions about margin recovery and merger timing that management chose not to answer. The ₹8,000+ cr portfolio is real. The collections momentum is real. The redevelopment entry is a strategic upgrade. But so is the 15% PAT decline, and until that gap closes, Marathon is a steady operator in a cautious mood, not a step-change growth story.
The single number to track from here is next quarter's organic PAT. If Q2 shows margin recovery (OPM and NPM re-expansion), the Q1 decline was cyclical and the growth narrative holds. If margins stay compressed, the market's caution is justified, and the stock stays a hold until management proves it can translate top-line growth into bottom-line profit.
40% growth masks 15% profit decline—margin pressure needs clarity
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met Q1 profit numbers but missed prior call's "continued momentum" for FY27—PAT decline vs revenue growth
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Marathon delivered 40% YoY revenue growth on strong Monte South presales and collections momentum. But PAT fell 14.8% YoY despite top-line growth—margin compression from either cost inflation or unfavorable project mix is the key risk. Management is executing well (ready-to-move driving collections) and building a pipeline (₹8,000+ cr GDV visible), but without clarity on margin recovery and explicit FY27 profit targets, the growth story remains incomplete.
₹197.5 Cr
Revenue · +40.3% YoY₹52.4 Cr
Reported PAT · −14.8% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Multi-quarter high total income of ₹217 cr
METDelivered ₹197.5 cr revenue; ₹217 cr is gross including other income (~Futurex rental)
Healthy profitability with ₹52 cr PAT
OVERSTATEDPAT ₹52.4 cr is down 14.8% YoY despite 40.3% revenue growth—margin compression
Monte South sustained sales momentum with 35,000 sq ft sold, ₹125 cr booking value
METConfirmed in call; represents strong premium residential demand for well-located projects
Ready-to-move inventory in Monte South Towers A & B selling at premium
METTower A has OC, Tower B completed to 45th floor; TAT ~3 months on collection
Existing portfolio ₹8,000 cr unsold GDV provides visibility
METStated as existing; merger will add 400+ acres and multiple ongoing projects
Balance sheet flexibility with ₹200 cr acquisition capital, debt-free position
METConfirmed post-₹900 cr QIP; net cash position after capital deployment
Earnings quality
What changed since the last call
Redevelopment entry
NewVersova (₹450 cr GDV) & Sewri (₹450 cr) acquired in Q1; first major society redevelopment milestone
Margin compression
DowngradePAT -14.8% YoY (₹61 cr → ₹52.4 cr implied prior) despite 40% revenue growth; prior call guided "continued momentum"
Capital deployment acceleration
Upgrade₹200 cr acquisition capital now live (post-₹900 cr QIP); targets 30-35% EBITDA margins on new deals
Collection visibility
UpgradeReady-to-move inventory (Tower A, B, Futurex, NeoSquare OC) supports collections trajectory; 3-month TAT on premium units
The Q&A
Analysts probed redevelopment timing (Mihir Shah dodged), FY27 outlook numbers (Kaivalya hedged hard—"won't answer future-looking"), and pricing discipline (Manav Jain challenged valuations). Management held firm on selectivity, warned against overpaying, but gave no forward guidance. Q&A tone: cautious, not defensive—management willing to explain hesitations but careful not to over-commit.
Redevelopment launch timeline — Mihir Shah, MP Securities
DodgedExisting portfolio totals ₹8,000 cr. New acquisitions add ₹900 cr. Pipeline is very large but selective—we're evaluating opportunities on location, viability, approvals, capital efficiency.
FY27 growth acceleration — Karan Mehra, Mehta Investments
PartialWon't answer future-looking guidance. But demand in Monte South footfalls increased dramatically, commercial strong. Bhandup new phase launched, Panvel launched. Outlook seems positive, much better than last year.
Collection trajectory — Karan Mehra, Mehta Investments
AnsweredReady-to-move inventory (Futurex, Monte South Towers A-B, NeoSquare) has 3-month TAT on sale. Collections will be on heavier side this year. Tower C already at 28th floor (40% completion).
Other income drop — Dev Ajmera, Individual Investor
AnsweredFuturex investment property: one floor's sale did not happen this quarter. Non-operating item.
Merger NCLT status — Dev Ajmera, Individual Investor
AnsweredAll stakeholder meetings in Sep (first week). Second hearing post-approval. Completion timing depends on NCLT availability; benches heavily loaded. No certainty on Dec vs 2027.
Redevelopment pipeline size — Manav Jain, MJ Investment
PartialRedevelopment opportunity is very huge in Mumbai. Selectivity critical—prime location most important. Many deals are expensive; we apply strict financial metrics and profit margin hurdles. Won't enter every deal.
Expensive redevelopment deals — Manav Jain, MJ Investment
AnsweredYes, many offers are high. But we've seen projects stuck when occupant asked too much. Better to have balanced approach. Developers offering very high percentages—we have strict financial metrics.
Capital deployment target — Pratisha Shah, Sai Advisory
AnsweredEBITDA margins of 30-35% target for new acquisitions. Surplus capital (~₹200 cr) will be fully deployed in FY27.
PTC sales vertical outlook — Pratisha Shah, Sai Advisory
AnsweredBhandup-based. Permanent Transit Camps = developers sell FSI to neighboring developers. Kanjurmarg land acquired Q4 FY26. Huge demand from redevelopment projects nearby needing FSI. May see PTC presales next few quarters.
Guidance
FY27 collections on heavier side
MediumReady-to-move inventory (Monte South A/B to 45th, Futurex, NeoSquare) TAT 3 months. Tower C 40% completion for % collections
Bhandup & Panvel bookings to show in next quarters
MediumNew phases launched; booking recognition deferred to registration; expect Q2-Q3 visibility
EBITDA 30-35% target for new acquisitions
HighDisciplined capital allocation hurdle; applies to Versova, Sewri, future redevelopment deals
₹200 cr capital to deploy in FY27
HighSurplus funds from ₹900 cr QIP; selective acquisitions at margin hurdles
Risks the call surfaced
Margin compression
HighPAT -14.8% YoY (₹52.4 cr) despite 40% revenue growth (₹197.5 cr). NPM 24.2%, OPM 23.6%. Management did not explain the delta. Cost inflation or unfavorable project mix could persist.
Merger execution risk
MediumNCLT second hearing date uncertain; benches heavily loaded. Slippage from Dec 2026 to 2027 could delay 400-acre land consolidation and ₹8,000+ cr portfolio integration.
Redevelopment valuation risk
MediumManagement acknowledged many redevelopment deals in market are "very pricey." Versova (₹450 cr) and Sewri (₹450 cr) just acquired; occupant cost escalation or delayed FSI approval could compress margins below 30-35% hurdle.
Collection timing
MediumCollections dependent on occupancy certificates and % completion milestones. Any construction delays (Tower C, Monte South Tower C) cascade to collection push-outs; impacts FY27 cash generation.
PTC segment unproven
LowPTC (Permanent Transit Camps) segment just entered post-Kanjurmarg acquisition (Q4 FY26). Depends on neighboring redevelopment demand scaling. No presales yet; addressable market size and durability unproven.
Management
Score 7/10. Clear on project-level execution and balance sheet. But vague on FY27 profit guidance—avoided forward numbers, hedged with "won't answer future-looking things." Openness on margin headwinds minimal. Monte South on track (A OC, B to 45th, C to 28th). Nexzone Cedar/Daffodil OC achieved. Collections strong (₹146 cr Q1). But Q1 PAT -14.8% YoY vs revenue +40.3%—execution not translating to profit.
1 · Sep 2026
NCLT shareholder meetings; second hearing scheduled post-approval
2 · Q2-Q3 FY27
Bhandup & Panvel phase launches; booking visibility expected
3 · Dec 2026
Panvel-Karjat corridor (Eastern express connection) deadline; demand catalyst
Management is executing well (ready-to-move driving collections) and building a pipeline (₹8,000+ cr GDV visible), but without clarity on margin recovery and explicit FY27 profit targets, the growth story remains incomplete.